Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$29.83M
Enterprise ValueC$19.53M
Total Cash (Recent Filing)C$4.96M
Total Debt (Recent Filing)C$316.49K
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow reported debt and a modest debt-to-equity ratio reduce near-term solvency pressure and covenant risk, giving management more optionality to fund R&D or pursue partnering without immediate refinancing. This durable balance-sheet characteristic supports multi-month operational continuity and strategic flexibility.
Strategic Focus On Psychedelic TherapeuticsThe company’s core business targets psychedelic-derived therapeutics for neurological and mental-health indications, aligning it with a multi-year structural trend toward novel psychiatric treatments. A clear therapeutic focus supports IP creation, specialized expertise, and potential high-margin product opportunities if clinical success is achieved.
Historic Positive Gross Profit When Revenue ExistedReported gross profit in prior revenue periods suggests the company can achieve favorable product economics once commercial activity scales. This indicates potential margin sustainability post-commercialization and supports the long-term thesis that R&D successes could translate into profitable operations if consistent revenue is secured.
Bears Say
No Revenue And Persistent LossesThe absence of revenue and recurring operating losses indicate the business is not yet generating economic value and lacks scale. Over a multi-month horizon this constrains reinvestment capacity, increases dilution risk from financing, and leaves long-term viability highly contingent on successful clinical outcomes or partnership deals.
Sustained Cash BurnSignificant negative operating and free cash flow signal ongoing reliance on external funding to sustain operations and clinical programs. This structural cash burn can force frequent financing, dilute shareholders, constrain ability to hit development milestones on schedule, and heighten execution risk over the next several months.
Historically Unstable / Negative EquityEpisodes of negative equity reflect cumulative losses that have eroded the capital base and can limit access to favorable capital or credit markets. Over a 2–6 month horizon this structural weakness increases the probability of dilutive financings or restrictive funding terms and reduces strategic flexibility.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$29.83M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 54 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 284,102,500 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acetylcysteine, intended for the treatment of mild traumatic brain injuries and post-traumatic stress disorder. Beyond drug development, it also engineers specialized devices designed to facilitate the efficient delivery of various medications. The organization was previously known as Greenstar Biosciences Corp. before formally changing its name to Lobe Sciences Ltd. in November 2020. Its main corporate office is situated in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---